Cargando…
CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS?
BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the E...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Colégio Brasileiro de Cirurgia Digestiva
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195465/ https://www.ncbi.nlm.nih.gov/pubmed/34133521 http://dx.doi.org/10.1590/0102-672020210001e1574 |
_version_ | 1783706507583422464 |
---|---|
author | PINTO, Thiago David Alves ALVES, Thaís David das Neves PINTO, Sebastião Alves OLIVEIRA, Enio Chaves |
author_facet | PINTO, Thiago David Alves ALVES, Thaís David das Neves PINTO, Sebastião Alves OLIVEIRA, Enio Chaves |
author_sort | PINTO, Thiago David Alves |
collection | PubMed |
description | BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the EGFR by immunohistochemistry predicting the mutation status of the expanded RAS (KRAS and NRAS), may allow treatment by a diagnostic method less costly and more accessible. AIM: Investigate the correlation between the clinical-pathological data, the cytoplasmic-membrane expression of the EGFR and the mutational status of the expanded RAS. METHOD: A total of 139 patients with colorectal carcinoma from the archives of Instituto Goiano de Oncologia e Hematologia were evaluated. RESULTS: Mutation of the expanded RAS was detected in 78 (56.1%) cases. The EGFR expression was stratified in 23 (16.5%) “positive”, 49 (35.2%) "negative" and 67 (48.2%) "uncertain". No significant correlation was found between the mutational status of the RAS and the EGFR expression in comparison to age, gender, location, histological type, histological grade and stage. From 23 "positive” cases, 21 (91.3%) showed wild-type RAS gene, and 49 "negative”, 41 (83.7%) presented mutation, resulting in a strong association between EGFR "positive", "negative” groups and the mutational status of the RAS (p<0.001), with 86.1% of accuracy. CONCLUSIONS: The cytoplasmic-membrane analysis of the EGFR expression stratified into "positive", "negative" and "uncertain" predicts mutational status of the RAS in 51.7% of the cases (p<0.001), with 86.1% of accuracy. |
format | Online Article Text |
id | pubmed-8195465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Colégio Brasileiro de Cirurgia Digestiva |
record_format | MEDLINE/PubMed |
spelling | pubmed-81954652021-06-24 CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? PINTO, Thiago David Alves ALVES, Thaís David das Neves PINTO, Sebastião Alves OLIVEIRA, Enio Chaves Arq Bras Cir Dig Original Article BACKGROUND: Inhibitors of the epidermal growth factor (EGFR) represent an effective therapeutic option for patients with metastatic colorectal carcinoma, free of activating mutations in KRAS and NRAS. However, the research of mutations is of high cost and scarcely accessible. The expression of the EGFR by immunohistochemistry predicting the mutation status of the expanded RAS (KRAS and NRAS), may allow treatment by a diagnostic method less costly and more accessible. AIM: Investigate the correlation between the clinical-pathological data, the cytoplasmic-membrane expression of the EGFR and the mutational status of the expanded RAS. METHOD: A total of 139 patients with colorectal carcinoma from the archives of Instituto Goiano de Oncologia e Hematologia were evaluated. RESULTS: Mutation of the expanded RAS was detected in 78 (56.1%) cases. The EGFR expression was stratified in 23 (16.5%) “positive”, 49 (35.2%) "negative" and 67 (48.2%) "uncertain". No significant correlation was found between the mutational status of the RAS and the EGFR expression in comparison to age, gender, location, histological type, histological grade and stage. From 23 "positive” cases, 21 (91.3%) showed wild-type RAS gene, and 49 "negative”, 41 (83.7%) presented mutation, resulting in a strong association between EGFR "positive", "negative” groups and the mutational status of the RAS (p<0.001), with 86.1% of accuracy. CONCLUSIONS: The cytoplasmic-membrane analysis of the EGFR expression stratified into "positive", "negative" and "uncertain" predicts mutational status of the RAS in 51.7% of the cases (p<0.001), with 86.1% of accuracy. Colégio Brasileiro de Cirurgia Digestiva 2021-06-11 /pmc/articles/PMC8195465/ /pubmed/34133521 http://dx.doi.org/10.1590/0102-672020210001e1574 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Original Article PINTO, Thiago David Alves ALVES, Thaís David das Neves PINTO, Sebastião Alves OLIVEIRA, Enio Chaves CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? |
title | CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? |
title_full | CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? |
title_fullStr | CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? |
title_full_unstemmed | CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? |
title_short | CYTOPLASMIC-MEMBRANE EGFR PREDICTS EXPANDED RAS MUTATION STATUS IN COLORECTAL CARCINOMAS? |
title_sort | cytoplasmic-membrane egfr predicts expanded ras mutation status in colorectal carcinomas? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195465/ https://www.ncbi.nlm.nih.gov/pubmed/34133521 http://dx.doi.org/10.1590/0102-672020210001e1574 |
work_keys_str_mv | AT pintothiagodavidalves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas AT alvesthaisdaviddasneves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas AT pintosebastiaoalves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas AT oliveiraeniochaves cytoplasmicmembraneegfrpredictsexpandedrasmutationstatusincolorectalcarcinomas |